Masitinib for Treatment of Severely Symptomatic Indolent Systemic Mastocytosis: A Randomised, Placebo-Controlled, Phase 3 Study
doi 10.31219/osf.io/ardb8
Full Text
Open PDFAbstract
Available in full text
Date
September 29, 2017
Authors
Publisher
Center for Open Science